BioWorld

July 8, 2004

Acusphere Licenses AI-700 EU Rights to Nycomed For $70M

Retaining U.S. marketing rights for itself, Acusphere Inc. signed a deal with Nycomed Group for the European rights to its lead product, AI-700. (BioWorld Today) Read More

Celera Partners Antigens With Abbott In Oncology Agreement

Cardiome Starts Third Phase III Of RSD1235 In Atrial Fibrillation

AmpliMed Setting Amplimexon Clinical Development Strategy

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 21, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...